MerLion Pharmaceuticals, a biopharmaceutical company based in Singapore and Berlin, has said that they have achieved positive results from a phase 2 trial with finafloxacin, a drug for treating patients hospitalized with complicated urinary tract infections (cUTI), including a high proportion with pyelonephritis.
Finafloxacin is a fluoroquinolone antibiotic that demonstrates a substantially improved therapeutic profile over the existing gold standard and greater utility in treating many severe infections, including those caused by a number of resistant gram-negative pathogens. Most other antibiotics, including other fluoroquinolones, have decreased activity in acidic conditions. However, Finafloxacin claims to surpass these acidic barriers.
The results from the phase 2 study indicate that patients treated with a five day course of finafloxacin had a higher, more rapid and more sustained level of bacterial eradication and improved clinical outcomes than those treated with the current standard of care (ciprofloxacin taken twice daily for 10 days). The trial’s primary and secondary endpoints were all successfully achieved. Finafloxacin was found to be both safe and tolerable, with only a small number of class-typical adverse events observed.
MerLion has developed IV and oral formulations of finafloxacin with equivalent bioavailability, offering physicians the choice of initially treating infections in hospital or at out-patient infusion centres for one to three days with the IV regimen, then allowing patients to complete their treatment at home; reducing the risk of complications and/or secondary infections. Hence, MerLion’s finafloxacin might help you say goodbye to painful UTIs.
This article is based on materials provided by: http://www.merlionpharma.com/?q=node/227
Disclaimer: This article does not reflect any personal views of the authors/editors